LIAISON® CA 19-9 - COFEPRIS Registration 1863R2019 SSA
Access comprehensive regulatory information for LIAISON® CA 19-9 (CA 19-9 LINK®) in the Mexico medical device market through Pure Global AI's free database. This Clase I medical device is registered under COFEPRIS analysis ID 1863R2019 SSA and manufactured by DIASORIN MÉXICO, S.A. DE C.V.. The device was registered on September 13, 2019.
This page provides complete registration details including product type (III. DIAGNOSTIC AGENTS), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.
PARA LA DETERMINACIÓN CUANTITATIVA DEL ANTÍGENO CA 19-9 EN SUERO HUMANO Y PLASMA HUMANO CON EDTA O CITRATADO DURANTE EL SEGUIMIENTO DE PACIENTES CON TUMORES GASTROINTESTINALES. EL ENSAYO DEBE REALIZARSE EN LA SERIE DE INSTRUMENTOS LIAISON® ANALYZER.
FOR THE QUANTITATIVE DETERMINATION OF CA 19-9 ANTIGEN IN HUMAN SERUM AND HUMAN PLASMA WITH EDTA OR CITRATE DURING THE FOLLOW-UP OF PATIENTS WITH GASTROINTESTINAL TUMORS. THE TEST SHOULD BE PERFORMED ON THE LIAISON® ANALYZER INSTRUMENT SERIES.